BKD
BEARISH
$12.95
Live
Brookdale Senior Living Inc. · NYSE
Target $13.88
(+7.1%)
$4.45
52W Range
$13.08
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$3.08B
P/E
N/A
ROE
-212.3%
Profit margin
-9.9%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
The Advanced Deterministic Scorecard reveals a deeply concerning financial profile for Brookdale Senior Living (BKD), with a Piotroski F-Score of just 2/9 indicating severe weakness in fundamental health. Despite strong recent price performance (+163.2% over 1Y), the company is unprofitable (ROE: -212.27%, Profit Margin: -9.95%), carries significant liquidity risk (Current Ratio: 0.84), and has consistently missed earnings estimates—0 out of the last 4 quarters beaten, with an average surprise of -101.87%. Valuation metrics are distorted (Price/Book: -462.50, Forward P/E: -23.33) due to negative equity and earnings, while the lack of an Altman Z-Score suggests potential distress risk. Analysts rate it a 'strong_buy' but with only 4 analysts and no meaningful insider activity, the bullish sentiment lacks conviction.
Key Strengths
Revenue growth of 4.20% YoY shows modest top-line resilience in a challenging senior care environment
Gross margin of 27.57% indicates some operational efficiency at the core service level
Price/Sales ratio of 1.00 is reasonable relative to unprofitable peers in the healthcare sector
Recent price momentum is strong, with +163.2% 1-year return signaling market optimism or speculative interest
Operating margin positive at 2.36%, suggesting limited path to profitability if cost controls hold
Key Risks
Piotroski F-Score of 2/9 signals extreme financial distress and poor earnings quality
Negative book value and ROE of -212.27% indicate eroding shareholder equity and likely balance sheet insolvency
Current Ratio of 0.84 and Quick Ratio of 0.50 reveal acute liquidity risk and inability to meet short-term obligations
Consistent and severe earnings misses: 0/4 recent quarters beaten, average surprise of -101.87%
No Altman Z-Score available, combined with negative equity, raises red flag for potential bankruptcy risk
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
15
Weak
15
30
20
10
0
AI Verdict
High-risk, fundamentally weak company with speculative price action
Key drivers: Piotroski F-Score of 2/9, Negative ROE and book value, Persistent earnings misses, Liquidity constraints, Distorted valuation metrics
Confidence
90%
Value
15/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 1.00 is not excessive for a growth-stage healthcare firm
Watchpoints
- Price/Book of -462.50 reflects negative equity
- Forward P/E of -23.33 indicates unprofitability
- Graham Number and Intrinsic Value unavailable due to negative earnings
Future
30/100
Ref Growth rates
Positives
- 4.20% YoY revenue growth suggests some demand stability
Watchpoints
- Earnings growth YoY: -84.6%
- Q/Q EPS growth: -200.0%
- No reliable earnings growth trajectory
Past
20/100
Ref Historical trends
Positives
- Some quarters showed small earnings beats (e.g., +25.6% in 2023-Q2)
Watchpoints
- 20 of the last 25 quarters missed or barely met estimates
- History of large negative surprises (e.g., -338.5% in 2020-Q1)
- No consistent earnings progression
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Operating margin slightly positive at 2.36%
Watchpoints
- Piotroski F-Score: 2/9 (Weak)
- Current Ratio: 0.84 < 1.0
- Quick Ratio: 0.50 indicates poor short-term liquidity
- ROE: -212.27% shows severe equity deterioration
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength: 0/100
- No dividend yield or payout history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$12.95
Analyst Target
$13.88
Upside/Downside
+7.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BKD and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BKD
Brookdale Senior Living Inc.
Primary
|
+153.4% | +367.5% | +163.2% | +72.4% | +18.9% | +6.2% |
|
PRVA
Privia Health Group, Inc.
Peer
|
+4.4% | -7.2% | +1.4% | -5.9% | +11.3% | +7.4% |
|
ICUI
ICU Medical, Inc.
Peer
|
-38.8% | -28.3% | -9.2% | +10.1% | -6.0% | +1.9% |
|
SUPN
Supernus Pharmaceuticals, Inc.
Peer
|
+66.0% | +41.6% | +67.1% | +2.4% | +4.3% | +1.4% |
|
BEAM
Beam Therapeutics Inc.
Peer
|
-69.2% | -29.2% | +20.1% | +45.3% | +12.2% | +1.1% |
BKD
Brookdale Senior Living Inc.
Primary
5Y
+153.4%
3Y
+367.5%
1Y
+163.2%
6M
+72.4%
1M
+18.9%
1W
+6.2%
PRV
Privia Health Group, Inc.
Peer
5Y
+4.4%
3Y
-7.2%
1Y
+1.4%
6M
-5.9%
1M
+11.3%
1W
+7.4%
ICU
ICU Medical, Inc.
Peer
5Y
-38.8%
3Y
-28.3%
1Y
-9.2%
6M
+10.1%
1M
-6.0%
1W
+1.9%
SUP
Supernus Pharmaceuticals, Inc.
Peer
5Y
+66.0%
3Y
+41.6%
1Y
+67.1%
6M
+2.4%
1M
+4.3%
1W
+1.4%
BEA
Beam Therapeutics Inc.
Peer
5Y
-69.2%
3Y
-29.2%
1Y
+20.1%
6M
+45.3%
1M
+12.2%
1W
+1.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-23.33
PEG Ratio
N/A
P/B Ratio
-462.5
P/S Ratio
1.0
EV/Revenue
2.7
EV/EBITDA
18.07
Market Cap
$3.08B
Profitability
Profit margins and return metrics
Profit Margin
-9.95%
Operating Margin
2.36%
Gross Margin
27.57%
ROE
-212.27%
ROA
0.92%
Growth
Revenue and earnings growth rates
Revenue Growth
+4.2%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
0.84
Weak
Quick Ratio
0.5
Poor
Cash/Share
$1.07
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-17
$N/A
2025-11-06
$-0.48
-181.9% surprise
2025-08-06
$-0.16
-14.8% surprise
2025-05-06
$-0.28
-108.8% surprise
Healthcare Sector Comparison
Comparing BKD against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-212.27%
This Stock
vs
-88.14%
Sector Avg
+140.8%
(Excellent)
Profit Margin
-9.95%
This Stock
vs
-16.28%
Sector Avg
-38.9%
(Weaker)
Revenue Growth
4.2%
This Stock
vs
124.04%
Sector Avg
-96.6%
(Slower)
Current Ratio
0.84
This Stock
vs
4.47
Sector Avg
-81.2%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BKD
Brookdale Senior Living Inc.
|
BEARISH | $3.08B | - | -212.3% | -9.9% | $12.95 | |
|
PRVA
Privia Health Group, Inc.
|
NEUTRAL | $3.02B | 126.42 | 4.0% | 1.1% | $24.02 | Compare |
|
ICUI
ICU Medical, Inc.
|
BEARISH | $3.14B | 4189.33 | 0.0% | 0.0% | $125.68 | Compare |
|
SUPN
Supernus Pharmaceuticals, Inc.
|
NEUTRAL | $2.96B | - | -3.7% | -5.4% | $51.39 | Compare |
|
BEAM
Beam Therapeutics Inc.
|
BEARISH | $3.2B | - | -47.2% | -% | $31.56 | Compare |
BKD
Brookdale Senior...
BEARISH
Mkt Cap
$3.1B
P/E
-
ROE
-212.3%
Price
$12.95
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-10-06 | STENGLE NIKOLAS W. | Chief Executive Officer | Stock Award | 157,731 | - |
| 2025-07-31 | HAUSMAN JOSHUA | Director | Stock Award | 12,903 | - |
STENGLE NIKOLAS W.
Chief Executive Officer
2025-10-06
157,731 shares
HAUSMAN JOSHUA
Director
2025-07-31
12,903 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
4 analysts
Barclays
2026-01-22
Overweight
Overweight
B of A Securities
2026-01-06
Underperform
Buy
RBC Capital
2025-11-17
Outperform
Outperform
Barclays
2025-11-11
Equal-Weight
Overweight
Barclays
2025-11-10
Equal-Weight
Equal-Weight
Barclays
2025-08-07
Equal-Weight
Equal-Weight
Past News Coverage
Recent headlines mentioning BKD from our newsroom.
Newest → oldest
No matching news yet.